180 related articles for article (PubMed ID: 32554601)
21. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
22. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
[TBL] [Abstract][Full Text] [Related]
23. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
24. Ellagic acid inhibits cell proliferation, migration, and invasion of anaplastic thyroid cancer cells via the Wnt/β-catenin and PI3K/Akt pathways.
Meng X; Cui Z; Shi H; Ma X; Li W; Liu X; Jiang Y
Acta Biochim Pol; 2023 Feb; 70(1):109-115. PubMed ID: 36773307
[TBL] [Abstract][Full Text] [Related]
25. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
Fuziwara CS; Saito KC; Kimura ET
Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
[No Abstract] [Full Text] [Related]
26. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
27. Ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.
Park SC; Lee JM
Genes Genomics; 2022 Mar; 44(3):369-377. PubMed ID: 34851506
[TBL] [Abstract][Full Text] [Related]
28. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
29. Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Gu G; Gelsomino L; Covington KR; Beyer AR; Wang J; Rechoum Y; Huffman K; Carstens R; Andò S; Fuqua SA
Breast Cancer Res Treat; 2015 Apr; 150(3):535-45. PubMed ID: 25820519
[TBL] [Abstract][Full Text] [Related]
30. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.
Patel PN; Yu XM; Jaskula-Sztul R; Chen H
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S497-504. PubMed ID: 24419754
[TBL] [Abstract][Full Text] [Related]
31. Novel oncogenic actions of TRbeta mutants in tumorigenesis.
Guigon CJ; Cheng SY
IUBMB Life; 2009 May; 61(5):528-36. PubMed ID: 19391168
[TBL] [Abstract][Full Text] [Related]
32. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
[TBL] [Abstract][Full Text] [Related]
33. Thyroid hormone receptor α1: a novel regulator of thyroid cancer cell differentiation.
Hwang E; Doolittle WKL; Zhu YJ; Zhu X; Zhao L; Yu Y; Cheng SY
Oncogene; 2023 Oct; 42(41):3075-3086. PubMed ID: 37634007
[TBL] [Abstract][Full Text] [Related]
34. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
35. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.
Wennerberg E; Pfefferle A; Ekblad L; Yoshimoto Y; Kremer V; Kaminskyy VO; Juhlin CC; Höög A; Bodin I; Svjatoha V; Larsson C; Zedenius J; Wennerberg J; Lundqvist A
Clin Cancer Res; 2014 Nov; 20(22):5733-44. PubMed ID: 25212604
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
37. OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.
Gugnoni M; Manzotti G; Vitale E; Sauta E; Torricelli F; Reggiani F; Pistoni M; Piana S; Ciarrocchi A
J Exp Clin Cancer Res; 2022 Mar; 41(1):108. PubMed ID: 35337349
[TBL] [Abstract][Full Text] [Related]
38. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
Kato Y; Ying H; Willingham MC; Cheng SY
Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
[TBL] [Abstract][Full Text] [Related]
39. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance.
Miller LD; McPhie P; Suzuki H; Kato Y; Liu ET; Cheng SY
Genome Biol; 2004; 5(5):R31. PubMed ID: 15128445
[TBL] [Abstract][Full Text] [Related]
40. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
